1 |
Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891-895
DOI
ScienceOn
|
2 |
Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease. Trans Roy Soc Trop Med Hyg 1969; 63: 708-737
DOI
ScienceOn
|
3 |
El-Safi SH, Peters W, El-Toam B, El-Kadarow A, Evans DA. Studies on leishmaniasis in the Sudan. 2. Clinical and parasitological studies on cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg 1991; 85: 457-464
DOI
ScienceOn
|
4 |
Isaac-Marquez AP, Lezama-Davila CM. Detection of pathogenic bacteria in skin lesions of patients with chiclero's ulcer. Reluctant response to antimonial treatment. Mem Inst Oswaldo Cruz 2003; 98: 1093-1095
DOI
|
5 |
Addy M, Nandy A. Ten years of kala-azar in west Bengal. Part I. Did postkala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull WHO 1992; 70: 341-346
PUBMED
|
6 |
El-On J, Sneier R, Elias E. Leishmaniasis major: bacterial contamination of cutaneous lesions in experimental animals. Isr J Med Sci 1992; 28: 847-851
PUBMED
|
7 |
Desjeux P. Worldwide increasing risk factors for leishmaniasis. Med Microbiol Immunol 2001; 190: 77-79
DOI
PUBMED
|